Результаты поиска

Proteomic and transcriptomic analyses to explain the pleiotropic effects of Ankaferd blood stopper.

Ankaferd blood stopper is a standardized mixture of the plants Thymus vulgaris, Glycyrrhiza glabra, Vitis vinifera, Alpinia officinarum, and Urtica dioica and has been used as a topical hemostatic agent and with its clinical application established in randomized controlled trials and case reports. Ankaferd has been successfully used in gastrointestinal endobronchial mucosal and cutaneous bleedings and also in abdominal, thoracic, dental and oropharyngeal, and pelvic surgeries. Ankaferd's hemostatic action is thought to form a protein complex with coagulation factors that facilitate adhesion of

Совпадение в полном тексте источника
… for mucoperiosteal flap and/or dental elevators were included in this study | Patients were selected so that 80 patients have INR values of ≤2, whereas the remaining patients have the INR values ranging from 2 to 3 and the procedures were applied | ABS is an effective hemostatic agent comparable to tranexamic … acid in controlling post-extraction bleeding in AOT patients of INR values ≤3 with no evidence support the superiority of tranexamic acid over ABS | For patients with INR values >2 ABS can represent itself as a sufficient local hemostatic agent that is comparable with tranexamic acid Atalay et al. 23 …

Spine surgery for metastatic spine cancer in the era of advanced radiation therapy.

Metastatic spine cancer (MSC), a common complication of advanced malignancies, poses significant challenges due to pain, neurological deficits, and mechanical instability. While radiation therapy is a cornerstone of treatment, the role of spine surgery is evolving, fueled by advances in surgical techniques and radiation modalities such as stereotactic body radiation therapy (SBRT). This review examines the evolving role of spine surgery in MSC management, focusing on separation surgery, surgical innovations, and future directions. The treatment paradigm for MSC shifted with the advent of SBRT,

Совпадение в полном тексте источника
… Additionally, preoperative intravenous tranexamic acid has been shown to reduce intraoperative bleeding [ 5 ], but its potential to increase thromboembolic risk is a concern, especially in high-risk MSC patients [ 5 ]. … However, Pennington et al. [ 5 ] found that limiting tranexamic acid dose to <20 mg/kg does not increase the risk of thromboembolism. …

Unveiling the Complexities of Hereditary Angioedema.

Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic disorder, constituting approximately 2% of all clinical cases of angioedema, with a global prevalence estimated between 1 in 50,000 and 1 in 150,000 individuals. The condition affects individuals of all genders and ethnic backgrounds without significant variation. HAE is classified into three types. Type I HAE, which accounts for 85% of cases, is characterized by a deficiency of the C1 esterase inhibitor (C1-INH) gene. Type II HAE, making up 15% of cases, involves a dysfunctional C1-INH. Type III HAE, which represen

Совпадение в полном тексте источника
… Tranexamic acid (TXA) can be used both acutely and prophylactically in HAE treatment, despite some debate over its efficacy [ 1 , 110 , 117 ]. … The use of tranexamic acid for on-demand and prophylactic treatment of hereditary angioedema: A systematic review J. Cutan Immunol. Allergy 2018 1 126 138 10.1002/cia2.12029 117. Wang K. Geiger H. McMahon A. Tranexamic acid for ACE inhibitor induced angioedema Am. J. Emerg. …

Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada.

BackgroundHereditary angioedema (HAE) is a rare autosomal dominant disease resulting in recurring episodes of swelling, leading to considerable patient morbidity and mortality. Lanadelumab is a plasma kallikrein inhibitor that is approved as 1st line therapy in Canada for long term prophylaxis of HAE attacks.ObjectiveTo describe our clinical findings from a case series of adult patients with HAE type 1/2 who have been initiated on lanadelumab.MethodsA chart review of HAE type 1/2 patients at three academic centers in Canada was undertaken with demographic and clinical data extracted. Patients

Совпадение в полном тексте источника
… Available second line options for LTP in some patients include attenuated androgens such as danazol and tranexamic acid (TXA), an antifibrinolytic [ 3 ]. … C1 esterase inhibitor enzyme, TXA tranexamic acid a Prednisone was given to this patient as acute treatment prior to HAE diagnosis and was ineffective at treating attacks Case | Type of attacks | Most debilitating attacks | Pre-lana LTP | Pre-lana acute treatment | Lana transition date | Lana dosage …

Interventions for the long-term prevention of hereditary angioedema attacks.

BACKGROUND: Hereditary angioedema (HAE) is a serious and potentially life-threatening condition that causes acute attacks of swelling, pain … nazol, and lanadelumab for the prevention of HAE attacks. We did not find any studies on the use of tranexamic acid for prevention of HAE attacks. All drugs except avoralstat reduced the number of HAE attacks compared with placebo. For breakthrough attacks that occurred despite prophylactic treatment, intravenous and subcutaneous forms of C1-INH and lanadelumab r …

Heyde Syndrome Unveiled: A Case Report with Current Literature Review and Molecular Insights.

Heyde syndrome, marked by aortic stenosis, gastrointestinal bleeding from angiodysplasia, and acquired von Willebrand syndrome, is often underreported. Shear stress from a narrowed aortic valve degrades von Willebrand factor multimers, leading to angiodysplasia formation and von Willebrand factor deficiency. This case report aims to raise clinician awareness of Heyde syndrome, its complexity, and the need for a multidisciplinary approach. We present a 75-year-old man with aortic stenosis, gastrointestinal bleeding from angiodysplasia, and acquired von Willebrand syndrome type 2A. The patient w

Совпадение в полном тексте источника
… Tranexamic acid, another effective antifibrinolytic, binds to plasminogen and can be administered in combination with desmopressin or VWF-containing concentrates [ 62 ]. 3.4.4. … Regarding the treatment of AVWD in Heyde syndrome, tranexamic acid may be a possible option for managing chronic bleeding due to angiodysplasias. …

Evaluation of the Enhanced Recovery After Surgery (ERAS) Guidance for Patients With Spinal Metastasis.

Surgery continues to remain the most effective treatment for spinal metastasis (SM). As the number of surgeries continues to grow, the need for consensus guidelines for optimal perioperative care is imperative. Enhanced recovery after surgery (ERAS) protocols were created for this purpose. The objective of this study is to review evidence-based ERAS guidelines for SM surgery. A group of multiple experienced spine surgeons was invited to participate in this study. This group identified 19 ERAS items for SM surgery. The principal literature search utilized MEDLINE, Embase, and Cochrane databases

Совпадение в полном тексте источника
… Tranexamic acid was effective in reducing blood loss when used locally during surgery [ 81 ]. An RCT containing 60 patients indicated that the intraoperative blood loss in the tranexamic acid oral group during major spinal surgery was significantly lower than that in the control group [ 82 ]. … Intravenous tranexamic acid can be continuously pumped according to the situation. Summary/recommendation : Prevent bleeding before surgery and using Tranexamic acid for Hemostasis. Quality of evidence : Moderate. Recommendation grade : Strong. …

Amyloidosis for the Gastroenterologist: A Comprehensive Systematic Review of Diagnosis and Management of Gastrointestinal Manifestations.

BackgroundAmyloidosis is a rare, multisystem disorder characterized by extracellular deposition of misfolded protein fibrils. Gastrointestinal (GI) amyloidosis is uncommon but under-recognized due to nonspecific symptoms, but early diagnosis is critical to improve quality of life and prognosis. This comprehensive systematic review aimed to summarize current literature on GI and hepatic manifestations of amyloidosis, highlighting diagnostic and management strategies across the major subtypes of amyloidosis, in particular AL (immunoglobulin light chain), ATTR (transthyretin), and AA (serum amylo

Совпадение в полном тексте источника
… If no contraindications exist, antifibrinolytic agents such as tranexamic acid or epsilon aminocaproic acid may be considered [ 113 ]. Management of hepatic hemorrhage focuses on blood product resuscitation and hemorrhage control. … Morishita , et al., “ Coagulation and Fibrinolytic Features in AL Amyloidosis With Abnormal Bleeding and Usefulness of Tranexamic Acid ,” International Journal of Hematology 111 , no. 4 ( 2020 ): 550 – 558 . 31897889 10.1007/s12185-019-02811-x 114 Á. Franco‐López and J. M. …

Thalidomide for refractory gastrointestinal bleeding from vascular malformations in patients with significant comorbidities.

BackgroundRefractory gastrointestinal bleeding (GIB) secondary to gastrointestinal vascular malformations (GIVM) such as gastrointestinal angiodysplasia (GIAD) and gastric antral vascular ectasia (GAVE) remains challenging to treat when endoscopic therapy fails. Recently thalidomide has been suggested as a treatment option for refractory GIB.AimTo determine the outcome of patients treated with thalidomide for refractory GIB due to GIVM.MethodsIRB approved, single center, retrospective review of electronic medical records from January 2012 to November 2018. Patients age > 18 years old, who had

Совпадение в полном тексте источника
… However, GIVM refractory to endoscopic treatment is common and medications such as octreotide, tranexamic acid, hormonal therapy such as estrogen-progesterone, and thalidomide have all been studied in the management of recurrent GIB refractory to endoscopic therapy. … Tranexamic acid in treatment-resistant chronic transfusion-dependent gastrointestinal angiodysplasia bleeding. BMJ Case Rep. 2017;2017:bcr2017221832. doi: 10.1136/bcr-2017-221832. 10. Tran A, Villeneuve JP, Bilodeau M, Willems B, Marleau D, Fenyves D, Parent R, Pomier-Layrargues G. …

Acquired platelet disorders.

Platelets are essential to primary hemostasis, and defects in their number or function can lead to clinically significant bleeding or thrombosis. Acquired platelet disorders are far more common than the inherited forms and arise in a wide range of settings, including drug exposure, autoimmune, systemic, and critical illnesses. This review examines current understanding of the mechanisms driving acquired platelet dysfunction and outlines the diagnostic and therapeutic approaches that are shaping contemporary standards of care. Drug-related and immune-mediated platelet defects remain the most re

Совпадение в полном тексте источника
… acid is an antifibrinolytic agent that reduces mucosal bleeding in dental procedures or menorrhagia; and local hemostatic measures like fibrin sealants and topical thrombin. … Early use of tranexamic acid is also effective in reducing bleeding ( 112 , 113 ). …

Приобретенный изолированный фактор VII Недостаток в ячейке Плазмы: краткое представление Two Дела, связанные с Плазмой-Келл-Леукемией, и обзор литературы.

Приобретенный изолированный фактор VII (FVII) недостаток является редким, но важным открытием у пациентов с расстройствами плазменных клеток, имеющими значительные терапевтические и прогнозные последствия. Цель настоящего анализа и обзора случаев, о которых сообщается в литературе, состоит в том, чтобы высветить связанные с болезнями характеристики, связанные с этим редким свертываемым дефектом, клиническими проявлениями и результатами, а также потенциальными основополагающими механизмами и дать руководящие указания в отношении методов лечения этих пациентов с точки зрения профилактических и т

Совпадение в полном тексте источника
… Prophylaxis with IV tranexamic acid was given during the stay in the hospital. … Finally, fibrinolytic inhibitors, i.e., tranexamic acid and fibrin glue, may be helpful in promoting and securing hemostasis. …

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.

The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population. Herein, we highlight the challenges in caring for patients with acute leukaemias and myeloid neoplasms amid the COVID-19 pandemic. We summarise key changes related to service allocation, clinical and supportive care, clinical trial participation, and ethical considerations regarding the use of lifesaving measures for these patients. We recognise that these

Совпадение в полном тексте источника
… acid, if the risk of bleeding is high in patients negative for SARS-CoV-2 infection. 31 Although early studies 32 , 33 have presented conflicting data on the detection of SARS-CoV-2 RNA and infectious virus in blood specimens, and blood borne transmission of SARS-CoV-2 has yet to be reported, the US … The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled trial. …

Bisphosphonates May Reduce Intraoperative Blood Loss in Surgery for Metastatic Spinal Disease: A Retrospective Cohort Study.

PurposeThis study was undertaken to investigate the relationship between bisphosphonate use and intraoperative blood loss following surgery for metastatic spinal disease.MethodsWe retrospectively analyzed cancer patients who were treated by metastatic spinal tumor surgery at our institution. Recorded data included intraoperative blood loss, timing and duration of bisphosphonate use, and other important confounding factors. We showed the results of crude model, minimally adjusted model, and fully adjusted model to fully observe the effects of bisphosphonates under different adjustment strategie

Совпадение в полном тексте источника
… acid and preoperative embolism, the results of multivariate linear regression indicated that the important predictors of blood loss during surgery were primary tumor type, type of surgery and operative time. … Thirdly, due to the limitation of the original data, we cannot observe the relationship between tranexamic acid and intraoperative blood loss, although some literature showed a correlation between them. …

Pericytes as targets in hereditary hemorrhagic telangiectasia.

Defective paracrine Transforming Growth Factor-β (TGF-β) signaling between endothelial cells and the neighboring mural cells have been thought to lead to the development of vascular lesions that are characteristic of Hereditary Hemorrhagic Telangiectasia (HHT). This review highlights recent progress in our understanding of TGF-β signaling in mural cell recruitment and vessel stabilization and how perturbed TGF-β signaling might contribute to defective endothelial-mural cell interaction affecting vessel functionalities. Our recent findings have provided exciting insights into the role of thalid

Совпадение в полном тексте источника
… Recent randomized controlled trials have demonstrated the efficacy of tranexamic acid in the treatment of severe bleeds in individuals with HHT (Gaillard et al., 2014 ; Geisthoff et al., 2014 ). Aminocaproic acid may also be effective (Saba et al., 1994 ). … Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study . Thromb. Res . 134 , 565 – 571 . 10.1016/j.thromres.2014.06.012 25005464 Gerhardt H. Betsholtz C. ( 2003 ). …

Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options.

Glanzmann's thrombasthenia (GT) is a genetic platelet surface receptor disorder of GPIIb/IIIa (ITG αIIbβ3), either qualitative or quantitative, which results in faulty platelet aggregation and diminished clot retraction. Spontaneous mucocutaneous bleeding is common and can lead to fatal bleeding episodes. Control and prevention of bleeding among patients with GT is imperative, and remains challenging. Local measures, including anti-fibrinolytic therapy, with or without platelet transfusions, used to be the mainstay of therapy. However, in recent years the use of recombinant factor VIIa (rFVIIa

Совпадение в полном тексте источника
… Local measures include compression, gelatin sponges, fibrin sealants, and topical thrombin. 6 Anti-fibrinolytic agents include tranexamic acid and epsilon aminocaproic acid. … The patient was refractory to platelet transfusions, tranexamic acid, and embolization, but responded to bevacizumab. …

Daratumumab-based treatment of monoclonal gammopathy-associated angioedema due to acquired C1-inhibitor deficiency.

Daratumumab-based treatment could control severe, treatment-refractory, life-threatening angioedema due to acquired C1-inhibitor deficiency associated with monoclonal gammopathy.

Совпадение в полном тексте источника
… Tranexamic acid (1000 mg orally 3 times daily) was not effective. At first presentation in our tertiary referral hospital, the patient had an estimated attack rate of 2 per month and a C1INH activity of 0.12 U/mL [range 0.63-1.82 U/mL]. …

How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India?

The current pandemic coronavirus, SARS-CoV-2, is known to cause severe infection (COVID-19) in patients with comorbidities, particularly cancer or an immunosuppressed state. Most healthcare systems in the country are likely to be overwhelmed soon if the pandemic moves to a stage of community transmission. Currently, limited evidence is available for managing patients with hematological disorders during the COVID-19 pandemic. The current review summarises the possible challenges clinicians are likely to face, key considerations to guide decision making, and possible solutions to the anticipated

Совпадение в полном тексте источника
… Encourage donations through NGOs, hospital staffs [ 23 ] Lower thresholds erythropoietin, thrombopoietin agonist, G-CSF to decrease the risks of chemotherapy induced cytopenias (Ref NCCN) Use prophylactic tranexamic acid in patients at risk of bleeding [ 24 ] Managing patients with hematologic disorders … Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusions. Eur J Haematol. 2009;45(2):86–89. doi: 10.1111/j.1600-0609.1990.tb00423.x. 25. Revised National Clinical Mangement guidelines for COVID-19. www.mohfw.gov.in . Accessed on 14 Apr 2020 26. Lancet T. …

Duodenal plasmablastic lymphoma in an human immunodeficency virus-negative patient: a case report.

BackgroundPlasmablastic lymphoma is a rare type of non-Hodgkin lymphoma that generally presents an aggressive clinical course. It is strongly associated with human immunodeficency virus (HIV) infection, and the most common site of involvement is the oral cavity. Although extraoral PBL has been reported in several places, small intestine involvement is extremely rare.Case presentationHere, we describe an exceptionally rare case of a 24-year-old immunocompetent Asian Male patient with newly diagnosed plasmablastic lymphoma of the duodenum. The patient was admitted to our oncology facility due to

Совпадение в полном тексте источника
… Supportive treatment was started, including 3 pint packed red blood cell (PRBC) blood transfusions to correct anaemia, injection of tranexamic acid 500 mg TDS, omeprazole (40 mg IV OD) and octreotide continuous IV infusion of 25 mcg/hr to control GI bleeding and ondansetron (8 mg IV BD) for vomiting. …

Alignment of a Ritchey-Chrétien telescope with primary mirror figure error guided by the rapid measurement of binodal astigmatism.

AbstractHereditary hemorrhagic telangiectasia (HHT) causes severe recurrent epistaxis, chronic gastrointestinal bleeding, solid organ arteriovenous malformations, and significant anemia. Although it is the second most common inherited bleeding disorder worldwide, no approved therapies exist. The multicenter, US randomized, controlled PATH-HHT trial demonstrated efficacy of short-term pomalidomide treatment of epistaxis in HHT. However, questions regarding long-term safety, effectiveness, and utility for HHT-associated gastrointestinal bleeding remain. The PATH-HHT ATLAS (after trial longitudin

Совпадение в полном тексте источника
… Only 2 other medical treatments, oral tranexamic acid and IV bevacizumab, have adequate published data to support their routine use for this indication. 14 , 22 , 31 , 32 As a once-daily oral medication, pomalidomide has obvious convenience and adherence-related advantages to these medications, avoiding … Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. J Thromb Haemost. 2014;12(9):1494–1502. doi: 10.1111/jth.12654. 32. Wang D, Ito S, Waldron C, et al. …

NAPCON 2025 – Best Original Research Abstracts

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.